BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 32641238)

  • 1. Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations.
    Kurnit KC; Reid P; Moroney JW; Fleming GF
    Gynecol Oncol; 2020 Sep; 158(3):531-537. PubMed ID: 32641238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
    Kooshkaki O; Derakhshani A; Safarpour H; Najafi S; Vahedi P; Brunetti O; Torabi M; Lotfinejad P; Paradiso AV; Racanelli V; Silvestris N; Baradaran B
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on immune checkpoint inhibitors in gynecological cancers.
    Heong V; Ngoi N; Tan DS
    J Gynecol Oncol; 2017 Mar; 28(2):e20. PubMed ID: 28028993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations.
    Santoro A; Angelico G; Inzani F; Arciuolo D; d'Amati A; Addante F; Travaglino A; Scaglione G; D'Alessandris N; Valente M; Tinnirello G; Raffone A; Narducci N; Piermattei A; Cianfrini F; Bragantini E; Zannoni GF
    Gynecol Oncol; 2024 May; 184():57-66. PubMed ID: 38295614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Gelsomino F; Di Federico A; Filippini DM; Dall'Olio FG; Lamberti G; Sperandi F; Balacchi C; Brocchi S; Ardizzoni A
    Clin Lung Cancer; 2020 Mar; 21(2):e45-e48. PubMed ID: 31902695
    [No Abstract]   [Full Text] [Related]  

  • 6. Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
    Chen S; Zhang N; Wang T; Zhang E; Wang X; Zheng J
    Front Immunol; 2020; 11():1900. PubMed ID: 32983112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-Checkpoint Blockade Therapy in Lymphoma.
    Kuzume A; Chi S; Yamauchi N; Minami Y
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of cancer immunotherapy for gynecologic malignancies.
    Nishio H; Iwata T; Aoki D
    Jpn J Clin Oncol; 2021 Feb; 51(2):167-172. PubMed ID: 33244581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers.
    Castellano T; Moore KN; Holman LL
    Clin Ther; 2018 Mar; 40(3):372-388. PubMed ID: 29530456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in gynecological cancers: where are we?
    Polastro L; Closset C; Kerger J
    Curr Opin Oncol; 2020 Sep; 32(5):459-470. PubMed ID: 32675594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
    Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
    Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
    Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
    Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-related adverse events of checkpoint inhibitors.
    Nat Rev Dis Primers; 2020 May; 6(1):39. PubMed ID: 32382085
    [No Abstract]   [Full Text] [Related]  

  • 14. Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma.
    Sanders S; Debinski W
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.
    Menderes G; Hicks C; Black JD; Schwab CL; Santin AD
    Expert Opin Biol Ther; 2016 Aug; 16(8):989-1004. PubMed ID: 27070175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.
    Ring KL; Pakish J; Jazaeri AA
    Cancer J; 2016; 22(2):101-7. PubMed ID: 27111905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
    Kagabu M; Nagasawa T; Sato C; Fukagawa Y; Kawamura H; Tomabechi H; Takemoto S; Shoji T; Baba T
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.